Abstract
After treatment with methotrexate (MTX), 6-mercaptopurine (6MP) demonstrated a synergistic effect and an enhanced incorporation into DNA and RNA in human lymphoblastic cell lines1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.P.M. Bökkerink, M.A.H. Bakker, T.W. Hulscher, et al, Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem. Pharmacol 37: 2321 (1988).
C.W. Keuzenkamp-Jansen, J.P.M. Bökkerink, R.A. De Abreu, et al, Pharmacokinetics of 24 hours intravenous high-dose 6-mercaptopurine after 24 hours intravenous methotrexate in childhood acte lymphoblastic leukemia. Med. Ped. Oncol., 21: 539 (1993).
J.P.M. Bökkerink, C.W. Keuzenkamp-Jansen, New use of an old drug: clinical application and pharmacokinetics of intravenous 6-mercaptopurine. In: R. Riccardi, J. Borsi (eds), The Role of Clinical Pharmacology in Pediatric Oncology. Rome: Tipolitografia Feroce, 105 (1992).
D.M. Tidd, A.R.P. Paterson, A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34: 738 (1974).
M.H.J. Vogt, E.H. Stet, R.A. De Abreu, et al, The importance of methylthio-IMP for methylmercaptopurine ribonucleoside cytotoxicity in Molt F4 human malignant T-lymphoblasts, Biochem. Biophys. Acta 1181: 189 (1993).
R.A. De Abreu, G.J. Peters, J.A.J.M. Bakkeren, et al, Discrepancies in ribonucleotide concentrations in human lymphocytes isolated from heparinized and defibrinized blood. Clin. Chim. Acta 145: 349 (1985)
E.H. Stet, R.A. De Abreu, Y.P.G. Janssen, et al, A Biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4 human malignant T-lymphoblastic cell line, Biochim. Biophys. Acta 1180: 277 (1993).
D. de Korte, W.A. Haverkort, A.H. van Gennip, et al, Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Analyt. Biochem. 147: 197 (1985).
L. Lennard, J.S. Lilleyman, Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. Leukemia, J. Clin. Oncol. 7: 1816 (1989).
W.E. Evans, M. Horner, Y. Qin Chu, et al, Altered mercaptopurine metabolism, toxic effects and dosage requirement in a TPMT deficient child with acute lymphoblastic leukemia, J. Pediatr. 119: 985 (1991).
L. Lennard, J.A. Van Loon, J.S. Lilleyman, et al, Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte TPMT activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol. Ther. 41: 18 (1987).
N. Erb, I. Ekem, D. Harms, et al, Differing metabolism of 6-thioguanine versus 6-mercaptopurine in maintenance treatment of childhood acute lymphoblastic leukemia. Ann. Hematol. 68(suppl 1) A93 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Keuzenkamp-Jansen, C.W., Bökkerink, J.P.M., Trijbels, J.M.F., v.d. Heijden, M.A.H., De Abreu, R.A. (1995). Intracellular Pharmacology and Biochemistry of Methotrexate and 6-Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_26
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive